ACC/AHA/HFSA Heart Failure Guidelines and Putting Them Into Practice
Published: 17 April 2022
-
Views:
9341
-
Likes:
7
-
Views:
9341
-
Likes:
7
-
5m 28s
Overview
The new 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure were presented at the recent ACC Scientific sessions.
In this series of short peer-to-peer discussions, Dr Mikhail Kosiborod, Dr Biykem Bozkurt, and Prof Giuseppe Rosano, discuss the main updates.
Learning Objectives
Following the completion of this programme, physicians will be in a position to:
- Summarise the main updates to the 2022 ACC heart failure guidelines
- Discuss data available on the use of SGLT2 inhibitors both in the treatment of HFpEF and across the Heart Failure spectrum
- Recall how heart failure practice is likely to change in the months ahead
Target Audience
- Global Cardiologists
- Heart Failure Specialists
- Primary Care Physicians
- Nurses
- Pharmacists
- Other allied HCPs
More from this programme
Part 1
Guideline Directed Medical Therapy in HF
Part 2
SGLT-2 Inhibitors Across the Range Of EF
Part 3
Using Guideline Directed Medical Therapy to Improve Outcomes
Faculty Biographies
Biykem Bozkurt
Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America.
Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine.
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
Prof Rosano's areas of expertise include heart failure, cardiac metabolism, cardiovascular pharmacology and pharmacotherapy, heart disease in women and cardiovascular effects of sex hormones. He has a specific interest in chronic coronary syndromes and in angina with normal coronary arteries.
Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian…
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.